Research Topics
| Joke BilckeSummaryAffiliation: University of Antwerp Country: Belgium Publications
|
Detail Information
Publications
Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice?Joke Bilcke
Center for Health Economic Research and Modeling Infectious Diseases CHERMID, Vaccine and Infectious Disease Institute VAXINFECTIO, University of Antwerp, Universiteitsplein 1, Wilrijk, Belgium
Vaccine 30:2795-800. 2012..Only one study estimated vaccine efficacy by age at vaccination and time since vaccination combined. Recently, data became available from the same trial for a follow-up period of 7 years...
The health and economic burden of chickenpox and herpes zoster in BelgiumJ Bilcke
Center for Health Economic Research and Modeling Infectious Diseases, Vaccine and Infectious Disease Institute VAXINFECTIO, University of Antwerp, Universiteitsplein 1, Wilrijk, Belgium
Epidemiol Infect 140:2096-109. 2012..The quality-adjusted life years lost for ambulatory CP patients consulting a physician is more than double that of those not consulting a physician (0·010 vs. 0·004). In conclusion, both diseases cause a substantial burden in Belgium...
Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in BelgiumJoke Bilcke
Center for Health Economics Research and Modeling Infectious Diseases CHERMID, Vaccine and Infectious Disease Institute VAXINFECTIO, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium
Vaccine 30:675-84. 2012..To assess the cost-effectiveness of vaccinating all or subgroups of adults aged 60 to 85 years against herpes zoster...
The health and economic burden of rotavirus disease in BelgiumJoke Bilcke
Unit for Health Economics and Modelling Infectious Diseases, Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
Eur J Pediatr 167:1409-19. 2008..This burden is estimated to represent direct costs of 7.7 million Euro and indirect costs of 12.8 million Euro. Rotavirus disease causes a substantial health and economic burden in Belgium...
Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in BelgiumJoke Bilcke
Centre for Health Economics and Modelling Infectious Diseases, Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Belgium
Med Decis Making 29:33-50. 2009..To estimate the cost-effectiveness of universal childhood rotavirus vaccination in Belgium, taking into account the impact of caregiver burden and the burden of sick children for whom no medical care is sought ("no medical care'' )...
Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sourcesJoke Bilcke
Centre for Health Economics Research and Modelling of Infectious Diseases CHERMID, Centre for the Evaluation of Vaccination CEV, Vaccine and Infectious Disease Institute VAXINFECTIO, University of Antwerp, Antwerp, Belgium
Pharmacoeconomics 27:281-97. 2009..Furthermore, future analyses may have to consider ways of accounting for herd immunity (e.g. by using a dynamic model)...
Estimating the incidence of symptomatic rotavirus infections: a systematic review and meta-analysisJoke Bilcke
Centre for Health Economics Research and Modeling of Infectious Diseases CHERMID, Vaccine and Infectious Disease Institute VAXINFECTIO, University of Antwerp, Wilrijk, Antwerp, Belgium
PLoS ONE 4:e6060. 2009....
Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guideJoke Bilcke
Center for Health Economic Research and Modeling for Infectious Diseases CHERMID, Vaccine and Infectious Disease Institute VAXINFECTIO, Antwerp University, Antwerp, Belgium
Med Decis Making 31:675-92. 2011..Besides guiding analysts, the guide and checklist may be useful to decision makers who need to assess how well uncertainty has been accounted for in a decision-analytic model before using the results to make a decision...
